Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

Published Date: 10 Apr 2024

Patients with surgically removed HPV-negative head and neck squamous cell cancer (HNSCC) experienced low rates of disease relapse after receiving the personalized neoantigen vaccine TG4050, which stimulated tumor-specific immune responses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

3.

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC

4.

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

5.

Can the way we talk about cancer change how we interact with the disease?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot